Hetero Labs Limited Ritonavir Export Data — India (DGFT 2022–2026)

Name: Hetero Labs Limited Ritonavir Export Records India — #1 Exporter, 494 Shipments, $24.7M FOB USD (DGFT 2022–2026)
Creator: TransData Nexus
Published: 2026-05-01T00:00:00Z
License: https://transdatanexus.com/terms-and-conditions

Suresh Sormare

Ritonavir

India Pharmaceutical Trade Intelligence

$340.6M84 Suppliers155 CountriesHS 30049099

ExportsIndia → BELGIUM51.5%India → INDONESIA7.8%

ImportsUNITED STATES → India$92.3K BRAZIL → India$80.0K

#1 Supplier: HETERO LABS

Hetero Labs Limited — Ritonavir Exporter #1 | $24.7M Trade Value | TransData Nexus | TransData Nexus

Hetero Labs Limited — Ritonavir Exporter Profile

Indian Pharmaceutical Exporter · #1 for Ritonavir · $24.7M export value · DGFT Verified

Hetero Labs Limited is the #1 Indian exporter of Ritonavir with $24.7M in export value and 494 verified shipments. Hetero Labs Limited holds a 7.3% market share in Ritonavir exports across 81 countries. The company exports 46 pharmaceutical products worth $319.3M across 18 therapeutic categories.

Hetero Labs Limited — Ritonavir Export Profile: Buyers & Destinations

Hetero Labs Limited Ritonavir export treemap — buyers and destination countries | TransData Nexus

Where Does Hetero Labs Limited Export Ritonavir?

Country	Value	Shipments	Share
BELGIUM	$8.7M	184	53.9%
COLOMBIA	$1.2M	25	7.5%
UNITED STATES	$1.2M	35	7.3%
NETHERLANDS	$682.4K	20	4.2%
PHILIPPINES	$514.2K	11

Who Are the Top Buyers of Ritonavir from Hetero Labs Limited?

Buyer	Country	Value	Orders
TO THE ORDER OF	BELGIUM	$10.4M	269
TO THE ORDER	SOUTH AFRICA	$1.0M	28
EXPEDITORS INTERNATIONAL NV	BELGIUM	$650.0K	13
PFIZER SER CO BV	BELGIUM	$450.0K	9
TO THE ORDER OF.,	PHILIPPINES	$358.8K	8
M/S	NETHERLANDS	$345.6K	10
M S TO THE ORDER OF ESSERS LSP I	BELGIUM	$300.0K	6
TO THE ORDER OF....	UNITED STATES	$248.4K	5
TO THE ORDER OF....................	COLOMBIA	$100.0K	2
M S TO THE ORDER OF BRUSSELS	BELGIUM	$100.0K	2

Hetero Labs Limited supplies Ritonavir to 86 buyers globally. The largest buyer is TO THE ORDER OF (BELGIUM), followed by TO THE ORDER (SOUTH AFRICA) and EXPEDITORS INTERNATIONAL NV (BELGIUM). These buyers represent pharmaceutical distributors, hospital groups, and government procurement agencies in their respective markets.

What Ritonavir Formulations Does Hetero Labs Limited Export?

Product Description / Formulation	Value	Shipments
RITONAVIR TABLET	$1.7M	46
RITONAVIR TABS	$1.4M	35
RITONAVIR TABLETNOS	$450.0K	9
VIRATAZ RITONAVIR 100 MG + ATAZANAVIR SU	$300.0K	6
RITONAVIR 50 MG + LOPINAVIR 200 MG TABS	$285.2K	8
VIRATAZ (RITONAVIR+ATAZANAVIR SULFATE 100MG+300MG TABLET)NOS	$269.1K	6
RITONAVIR 100MG TABLET	$178.8K	4
DARUNAVIR+RITONAVIR 400MG+50MG TABLET 60S	$164.4K	10
RITONAVIR 16.63%W/W(RITONAVIR 100 MG GRA	$150.0K	3
RITOCOM RITONAVIR+LOPINAVIR TABLET	$150.0K	3

Hetero Labs Limited exports 282 distinct Ritonavir formulations including tablets, capsules, syrups, and combination drugs. The top formulation is RITONAVIR TABLET with 46 shipments worth $1.7M.

How Does Hetero Labs Limited Compare to Nearest Ritonavir Exporters?

Exporters ranked immediately above and below #1 by export value

#	Supplier	Export Value	Shipments	Countries	Avg/Shipment
2	MYLAN LABORATORIES LIMITED	$27.5M	550	92	$50.0K
1	HETERO LABS LIMITED ★	$24.7M	494	81	$50.0K
4	EMCURE PHARMACEUTICALS LIMITED	$5.5M	110	43	$50.0K
5	AUROBINDO PHARMA LTD	$4.9M	104	39	$47.0K

Hetero Labs Limited ranks #1 among 84 Indian Ritonavir exporters. Average shipment value of $50.0K compared to the market average of $823.4K. The closest competitors by value are MYLAN LABORATORIES LIMITED and EMCURE PHARMACEUTICALS LIMITED.

Which Indian Ports Ship Ritonavir Exports?

Port	Shipments	% Share
SAHAR AIR	335	21.5%
SAHAR AIR CARGO ACC (INBOM4)	281	18.1%
HYDERABAD ACC (INHYD4)	217	14.0%
HYDERABAD AIR	123	7.9%
Bombay Air	87	5.6%
NHAVA SHEVA SEA (INNSA1)	58	3.7%
DELHI AIR CARGO ACC (INDEL4)	48	3.1%
HYDERABAD ICD	47	3.0%

Geopolitical & Trade Policy Impact on Hetero Labs Limited's Ritonavir Exports

The current geopolitical climate presents both challenges and opportunities for Hetero Labs Limited. The Israel-Iran tensions have led to increased risks in the Red Sea shipping routes, prompting major shipping lines to implement 'Emergency Risk Surcharges' ranging from $250 to $500 per TEU. This escalation in shipping costs directly impacts Indian pharmaceutical exporters like Hetero, potentially eroding profit margins and necessitating strategic adjustments in logistics and pricing strategies.

Conversely, the U.S.-China trade tensions have created openings for Indian pharmaceutical companies. The U.S. has imposed tariffs as high as 245% on APIs from certain countries, leading to a reshoring of pharmaceutical manufacturing. Indian firms, including Hetero, have responded by investing in U.S. facilities, with outbound foreign direct investment estimated between $500-700 million during the partial FY 2025-26. This strategic move not only circumvents tariffs but also strengthens Hetero's presence in the lucrative U.S. market.

The recent India-European Union Free Trade Agreement (FTA), concluded in January 2026, eliminates tariffs on Indian pharmaceuticals entering the EU. This development enhances Hetero's competitiveness in the European market, providing a significant boost to its export potential. However, compliance with the EU's Falsified Medicines Directive remains imperative, necessitating stringent quality controls and traceability measures to maintain market access.

Hetero Labs Limited — Regulatory Compliance & Quality Standards

Regulatory compliance is paramount for Hetero's sustained success in international markets. In October 2025, the U.S. Food and Drug Administration (FDA) issued a Form 483 to Hetero's Nakkapalli facility in Andhra Pradesh, citing six major compliance lapses, including quality control deficiencies and improper documentation practices. Such observations can jeopardize Hetero's ability to supply APIs and antiretroviral drugs to the U.S. market, underscoring the critical need for rigorous adherence to Good Manufacturing Practices (GMP) and prompt corrective actions to address regulatory concerns.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Analysis Methodology

1.Product Matching: Ritonavir shipments identified using fuzzy matching on DGFT product description fields, validated against Indian Pharmacopoeia nomenclature.
2.Supplier Identification: Hetero Labs Limited matched across shipments using name normalization, accounting for company name formatting variations.
3.Statistical Normalization: Shipment values are statistically normalized to ensure accurate market share representation. This removes the impact of unusually large one-off transactions that could distort company rankings.
4.Verified Records: This page is backed by 494 individual customs records matching Hetero Labs Limited exporting Ritonavir, covering 282 formulations to 86 countries via 86 buyers.

Government-Sourced Data

Official DGFT customs records

Transparent Methodology

Calculations fully disclosed above

Global Coverage

Exports to 155+ countries, 525+ buyers

Expert-Reviewed

Analyzed by pharmaceutical trade specialists

Ritonavir

Ritonavir

Hetero Labs Limited — Ritonavir Exporter Profile

Hetero Labs Limited — Ritonavir Export Profile: Buyers & Destinations

Where Does Hetero Labs Limited Export Ritonavir?

Who Are the Top Buyers of Ritonavir from Hetero Labs Limited?

What Is India's Total Ritonavir Export Value and How Much Does Hetero Labs Limited Contribute?

What Is the Average Shipment Value for Hetero Labs Limited's Ritonavir Exports?

How Does Hetero Labs Limited Compare to Other Indian Ritonavir Exporters?

What Ritonavir Formulations Does Hetero Labs Limited Export?

Regulatory Requirements: Exporting Ritonavir to Key Markets

United States — FDA

How Does Hetero Labs Limited Compare to Nearest Ritonavir Exporters?

Which Indian Ports Ship Ritonavir Exports?

What Other Antiviral & HIV Medications Products Does Hetero Labs Limited Export?

Ritonavir — Export Intelligence Video

Geopolitical & Trade Policy Impact on Hetero Labs Limited's Ritonavir Exports

Hetero Labs Limited — Regulatory Compliance & Quality Standards

About Hetero Labs Limited

Market Intelligence

Official References & Regulatory Resources

Research Methodology & Data Transparency

Suresh Sormare

Primary Data Source

Analysis Methodology

Get Ritonavir Export Data from Hetero Labs Limited

Ritonavir Stats

Company Overview

Top Products by Hetero Labs Limited

Related Analysis

Need Detailed Export Data?

Data Source